BIOMAT Database Logo BIOMAT Database Logo

Healing of autoimmune hepatitis associated with hepatitis C virus infection treated with direct-acting antivirals. 2019

Laura López Couceiro, and Elena Gómez Domínguez, and Raquel Muñoz Gómez, and Gregorio Castellano Tortajada, and Carolina Ibarrola de Andrés, and Inmaculada Fernández Vázquez
Medicina de Aparato Digestivo, Hospital Universitario 12 de octubre, España.

The use of direct-acting antivirals (DAA) for the hepatitis C virus (HCV) has yielded a significant improvement in the treatment of autoimmune hepatitis (AIH) associated with HCV infection. Interferon was the cornerstone of HCV therapy before the introduction of these agents into the clinical practice. Herein, we report the case of an HCV-infected patient who developed an interferon-induced AIH and since then, has received immunosuppressive therapy. Administration of DAA resulted in a sustained virologic response (SVR) and clinical AIH remission which allowed a discontinuation of immunosuppressive treatment.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007372 Interferons Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. Interferon
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D005260 Female Females
D005449 Fluorenes A family of diphenylenemethane derivatives.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069474 Sofosbuvir A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C. 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester,GS-7977,PSI 7977,PSI-7977,PSI7977,Sovaldi,7977, PSI,GS 7977,GS7977
D000072230 Sustained Virologic Response The continuous, long-term suppression of VIRAL LOAD, generally to undetectable levels, as the result of treatment with ANTIVIRAL AGENTS. Sustained Viral Suppression,Response, Sustained Virologic,Suppression, Sustained Viral,Sustained Viral Suppressions,Sustained Virologic Responses,Virologic Response, Sustained
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

Laura López Couceiro, and Elena Gómez Domínguez, and Raquel Muñoz Gómez, and Gregorio Castellano Tortajada, and Carolina Ibarrola de Andrés, and Inmaculada Fernández Vázquez
Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection.
April 2020, Internal medicine (Tokyo, Japan),
Laura López Couceiro, and Elena Gómez Domínguez, and Raquel Muñoz Gómez, and Gregorio Castellano Tortajada, and Carolina Ibarrola de Andrés, and Inmaculada Fernández Vázquez
Risk of autoimmune hepatitis reactivation in patients with chronic hepatitis C and autoimmune hepatitis treated with direct-acting antivirals.
March 2019, Polish archives of internal medicine,
Laura López Couceiro, and Elena Gómez Domínguez, and Raquel Muñoz Gómez, and Gregorio Castellano Tortajada, and Carolina Ibarrola de Andrés, and Inmaculada Fernández Vázquez
Retreatment of Hepatitis C Infection With Direct-Acting Antivirals.
July 2020, Federal practitioner : for the health care professionals of the VA, DoD, and PHS,
Laura López Couceiro, and Elena Gómez Domínguez, and Raquel Muñoz Gómez, and Gregorio Castellano Tortajada, and Carolina Ibarrola de Andrés, and Inmaculada Fernández Vázquez
Multimodal Treatment of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antivirals.
May 2022, Cureus,
Laura López Couceiro, and Elena Gómez Domínguez, and Raquel Muñoz Gómez, and Gregorio Castellano Tortajada, and Carolina Ibarrola de Andrés, and Inmaculada Fernández Vázquez
Hepatitis C Virus-associated Cryoglobulinemic Livedo Reticularis Improved with Direct-acting Antivirals.
December 2023, Internal medicine (Tokyo, Japan),
Laura López Couceiro, and Elena Gómez Domínguez, and Raquel Muñoz Gómez, and Gregorio Castellano Tortajada, and Carolina Ibarrola de Andrés, and Inmaculada Fernández Vázquez
Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals.
October 2017, Journal of gastroenterology and hepatology,
Laura López Couceiro, and Elena Gómez Domínguez, and Raquel Muñoz Gómez, and Gregorio Castellano Tortajada, and Carolina Ibarrola de Andrés, and Inmaculada Fernández Vázquez
Hepatitis B virus reactivation after direct-acting antivirals for chronic hepatitis C infection.
March 2018, The lancet. Gastroenterology & hepatology,
Laura López Couceiro, and Elena Gómez Domínguez, and Raquel Muñoz Gómez, and Gregorio Castellano Tortajada, and Carolina Ibarrola de Andrés, and Inmaculada Fernández Vázquez
New direct-acting antivirals in the development for hepatitis C virus infection.
May 2010, Therapeutic advances in gastroenterology,
Laura López Couceiro, and Elena Gómez Domínguez, and Raquel Muñoz Gómez, and Gregorio Castellano Tortajada, and Carolina Ibarrola de Andrés, and Inmaculada Fernández Vázquez
Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India.
July 2017, The Indian journal of medical research,
Laura López Couceiro, and Elena Gómez Domínguez, and Raquel Muñoz Gómez, and Gregorio Castellano Tortajada, and Carolina Ibarrola de Andrés, and Inmaculada Fernández Vázquez
Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct-acting antivirals: The GRUviC project.
August 2017, International journal of clinical practice,
Copied contents to your clipboard!